Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China

查看全文 作　　者：Shaohua [1]Zhang;Jianbin [1]Li;Ruonan [2]Xu;Qianjun [3]Chen;Gang [4]Sun;Ying [5]Lin;Feng [6]Jin;Xinlan [7]Liu;Zhimin [8]Fan;Yiding [9]Chen;Yali [10]Cao;Xinzheng [11]Li;Jianyun [12]Nie;Guiying [13]Xu;Xiaojia [14]Wang;Yuee [15]Teng;Tao [16]Sun;Hong [17]Liu;Jing [18]Luo;Cuizhi [19]Geng;Man [20]Li;Ting [21]Luo;Yinhua [22]Liu;Fu-Sheng [2]Wang;Zefei [1]Jiang 机构地区：[1]Department of Oncology,the Fifth Medical Center of PLA General Hospital,Beijing 100071,China;[2]Department of Infectious Diseases,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100039,China;[3]Department of Breast Cancer,Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou 510000,China;[4]Department of Breast Head and Neck Surgery,Cancer Hospital Affiliated to Xinjiang Medical University,Urumqi 830011,China;[5]Department of Breast Surgery,the First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510062,China;[6]Department of Breast Surgery,the First Affiliated Hospital of China Medical University,Shenyang 110001,China;[7]Department of Oncology,General Hospital of Ningxia Medical University,Ningxia 750003,China;[8]Department of Breast Surgery,the First Hospital of Jilin University,Changchun 130031,China;[9]Department of Oncology Surgery,the Second Affiliated Hospital of Medical College of Zhejiang University,Hangzhou 310009,China;[10]Department of Oncology,Nanchang Third Hospital,Nanchang 330009,China;[11]Department of Breast Surgery,Shanxi Cancer Hospital,Taiyuan 030013,China;[12]Department of Breast Surgery,Yunnan Cancer Hospital,Kunming 650118,China;[13]Department of Breast Surgery,Jilin Cancer Hospital,Changchun 130012,China;[14]Department of Oncology,Cancer Hospital Affiliated to the University of Chinese Academy of Sciences,Hangzhou 310005,China;[15]Department of Oncology,the First Affiliated Hospital of China Medical University,Shenyang 110001,China;[16]Department of Oncology,Liaoning Cancer Hospital,Shenyang 110801,China;[17]Department of Oncology,Tumor Hospital of Tianjin Medical University,Tianjin 300060,China;[18]Department of Breast Surgery,Sichuan Provincial People's Hospital,Chengdu 610042,China;[19]Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;[20]Department of Oncology,the Second Affiliated Hospital of Dalian Medical University,Dalian 116050,China;[21]Department of Head and Neck Tumor,West China Hospital of Sichuan University,Chengdu 610042,China;[22]Department of Breast Surgery,the First Hospital of Peking University,Beijing 100034,China 出　　处：《Infectious Diseases & Immunity》索引2023年第3卷第3期,共5页 基　　金：Emergency Key Program of Guangzhou Laboratory(EKPG21-30-4)。 摘　　要：In this study,we aimed to explore the safety and vaccination coverage data of Chinese patients with breast cancer receiving coronavirus disease 2019(COVID-19)vaccination.The patients were recruited from 41 hospitals across 20 Chinese provinces.The vaccination coverage was approximately 22.4%,and the frequency of total adverse events was 13.3%after the first dose and 9.9%after the second dose.The most frequent adverse reaction within 14 days of the first dose was local pain(5.7%).Unvaccinated patients were very likely to reject the vaccine rather than be hesitant in patients with old age(odds ratio[OR],1.238;95%confidence interval[CI],1.101-1.391),chronic disease history(OR,1.189;95%CI,1.057-1.337),and cancer relapse(OR,1.398;95%CI,1.233-1.585).Of the unvaccinated patients with breast cancer,54.1%opted to receive COVID-19 vaccines if more data were available.Considering the safety but low vaccination coverage for breast cancer,increased positive attitudes and acceptance toward COVID-19 vaccines are important. 关 键 词：Breast cancer COVID-19 vaccine SAFETY